Indication: Symptomatic treatment of severe sialorrhoea in adolescents and children over three years of age, with chronic neurological disorders. Not recommended for children younger than three years of age. Should be prescribed by physicians experienced in the treatment of neurological disorders. Dosage & Administration: Oral tablets; can be divided into equal doses (0.5mg for 1mg tablets; 1mg for 2mg tablets). Weight-based dosing schedule – initiation: 0.02mg/kg three times daily; modification: titrated in increments of 0.02mg/kg per week depending on therapeutic response and tolerability; maximum: 0.1mg/kg three times daily, not to exceed 1.5–3mg per dose. Other formulations are available for doses which cannot be achieved with tablet format, or for patients unable to swallow tablets. Contraindications: Hypersensitivity to glycopyrronium bromide or any of the excipients. Glaucoma. Urinary retention. Severe renal impairment (estimated glomerular filtration rate [eGFR] <30ml/min/1.73m², including those with end stage renal disease requiring dialysis). History of intestinal obstruction, ulcerative colitis, paralytic ileus, pyloric stenosis or myasthenia gravis. Pregnancy or breast-feeding. Concomitant treatment with potassium chloride (solid oral dose) or anticholinergics. Precautions and Warnings: Indicated for paediatric use only. Limited data are available on the use of glycopyrronium in adults with pathological drooling; should not be used in patients over 65 years of age. Co-administration with food markedly reduces systemic exposure; administer ≥1 hour prior or ≥2 hours following meals, or at consistent times with respect to food intake; avoid high fat food. If co-administration with food is required, dosing should be consistently performed during food intake. 30% dose reduction required for patients with mild to moderate renal impairment (eGFR <90–≥30ml/min/1.73m²). Hepatic impairment is not thought to result in clinically relevant increases in systemic exposure, however, clinical studies have not been conducted in this setting. Anticholinergic effects may be dose dependent and difficult to assess in a disabled child; advise carer to stop treatment and seek advice in the event of: constipation, urinary retention, pneumonia, allergic reaction, pyrexia, very hot weather, changes in behaviour – following evaluation, prescriber to decide if dose reduction or discontinuation are appropriate (discontinue if pneumonia is present). Published safety data for long-term use (>24 weeks) are not available; recommended for short-term intermittent use, total treatment duration should be kept as short as possible. Benefit-risk should be carefully considered, and patients closely monitored, in cases of continuous or repeated intermittent use. Should not be administered to children with mild to moderate sialorrhoea. Use with caution in patients with gastro-oesophageal reflux disease, pre-existing constipation, diarrhoea, compromised blood brain barrier (intraventicular shunt, brain tumour, encephalitis), acute myocardial infarction, hypertension, coronary artery disease, cardiac arrhythmias and conditions characterised by tachycardia (including thyrotoxicosis, cardiac insufficiency, cardiac surgery); advise carer to measure pulse rate if the child seems unwell, and to report occurrences of very fast or very slow heart rate. Patients should receive adequate daily dental hygiene and regular dental health checks. Behavioural changes should be monitored. Not